<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01620684</url>
  </required_header>
  <id_info>
    <org_study_id>Metyrapone</org_study_id>
    <secondary_id>Heart Foundation G11M5892</secondary_id>
    <nct_id>NCT01620684</nct_id>
  </id_info>
  <brief_title>Cortisol and Nutritional Sympathetic Responsiveness</brief_title>
  <official_title>The Effects of Cortisol Blockade on Nutritional Sympathetic Nervous System Responsiveness in Overweight and Obese Subjects With Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baker Heart Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baker Heart Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project will examine whether short-term (over a 12-hour period) pharmacological lowering&#xD;
      of the stress hormone 'cortisol' improves the nervous system response to food intake in&#xD;
      overweight or obese individuals who have metabolic syndrome.&#xD;
&#xD;
      The investigators know from our previous research that overweight/obese persons who are&#xD;
      insulin resistant, have a blunted sympathetic nervous response to carbohydrate ingestion.&#xD;
      This means that they are less able to dissipate energy from caloric intake, which would&#xD;
      favour the maintenance of the obese state. Cortisol adversely impacts on insulin action and&#xD;
      transport into the brain and cortisol levels are often elevated in persons with central&#xD;
      (abdominal) obesity.&#xD;
&#xD;
      A randomized, double-blind, placebo controlled, cross-over design will be used to compare the&#xD;
      effects of overnight treatment with metyrapone (15 mg/kg at midnight and 15 mg/kg at 6 am)&#xD;
      versus placebo on sympathetic nervous system activity in response to a standard 75-g oral&#xD;
      sugar (glucose) tolerance test. A 2 week washout will separate treatments.&#xD;
&#xD;
      Metyrapone is a drug that reversibly inhibits the enzyme 11beta-hydroxylase, and therefore&#xD;
      the production of cortisol. It is used clinically to test the activity of the adrenal gland&#xD;
      (the key site of cortisol production) and the pituitary gland. The investigators anticipate&#xD;
      that at the dosage used, it will lower blood cortisol concentration by 44 to 64% during the&#xD;
      experimental morning.&#xD;
&#xD;
      The study protocol comprises two screening visits and two experimental mornings. Key&#xD;
      procedures will include:&#xD;
&#xD;
        -  Assessment of insulin action (sensitivity) using the gold standard 'clamp' method.&#xD;
&#xD;
        -  Measurement of sympathetic nervous system activity by both biochemical methods (isotope&#xD;
           dilution which provides a measure of the apparent rate of release of 'noradrenaline'-the&#xD;
           key neurotransmitter in the sympathetic nervous system) and direct intra-neuronal nerve&#xD;
           recordings from the peroneal nerve in the lower leg.&#xD;
&#xD;
        -  Indirect calorimetry to assess resting metabolic rate and the response to sugar&#xD;
           ingestion.&#xD;
&#xD;
        -  DEXA scan to quantify fat and lean mass.&#xD;
&#xD;
        -  Assessment of arterial elasticity and calf blood flow by non-invasive methods.&#xD;
&#xD;
        -  A standard 75g oral sugar tolerance test.&#xD;
&#xD;
      The results will provide important new information regarding the role of cortisol on nervous&#xD;
      system function in overweight/obese individuals.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Similarities between metabolic syndrome obesity and hypercortisolemic conditions such as&#xD;
      Cushing's syndrome have raised interest in the pathogenic role of glucocorticoid excess in&#xD;
      this clinical setting. Cortisol is a well known counter-regulator of insulin action and&#xD;
      increased levels of serum cortisol have been linked to insulin resistance in many studies.&#xD;
      Moreover, treatment with the synthetic glucocorticoid dexamethasone reduced central nervous&#xD;
      system insulin uptake by 49% in dogs. We have previously identified in metabolic syndrome&#xD;
      subjects, an inverse relationship between morning fasting cortisol levels and sympathetic&#xD;
      neural responsiveness to oral glucose ingestion. This concurs with other evidence that&#xD;
      cortisol and synthetic glucocorticoids have sympathoinhibitory effects.&#xD;
&#xD;
      This project will test the hypothesis that short-term lowering of plasma cortisol levels by&#xD;
      overnight metyrapone treatment, will improve nutritional sympathetic nervous system responses&#xD;
      to carbohydrate ingestion in obese insulin resistant subjects with metabolic syndrome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2013</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nutritional sympathetic nervous system responsiveness</measure>
    <time_frame>12-hours</time_frame>
    <description>Effects of acute overnight metyrapone treatment will be studied</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>insulin sensitivity</measure>
    <time_frame>12 hours</time_frame>
    <description>Acute effects of overnight metyrapone treatment will be studied</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Obesity</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>metyrapone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Overnight metyrapone treatment (total dose of 30 mg/kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Overnight treatment with placebo capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metyrapone</intervention_name>
    <description>Overnight treatment (15 mg/kg at midnight and 15 mg/kg at 6 am)</description>
    <arm_group_label>metyrapone</arm_group_label>
    <other_name>Metopirone (Novartis)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo capsules</description>
    <arm_group_label>sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  un-medicated,&#xD;
&#xD;
          -  overweight or obese subjects (12 men and 12 postmenopausal women),&#xD;
&#xD;
          -  weight-stable,&#xD;
&#xD;
          -  non-smoking,&#xD;
&#xD;
          -  aged 45-65 years&#xD;
&#xD;
          -  will be recruited on the basis of having &gt; 3 MetS criteria as per the newly harmonized&#xD;
             definition.&#xD;
&#xD;
          -  elevated waist circumference will be defined as &gt; 102 cm in men and &gt; 88 cm in women.&#xD;
&#xD;
          -  all subjects will also be insulin resistant (HOMA index &gt; 2.5 and/or euglycaemic&#xD;
             hyperinsulinemic clamp derived M/I value &lt; 8 mg per kg fat free mass per minute per&#xD;
             mU/L x 100).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  adrenocortical insufficiency,&#xD;
&#xD;
          -  pituitary dysfunction or tumour,&#xD;
&#xD;
          -  sleep apnoea treated with CPAP,&#xD;
&#xD;
          -  cardiovascular disease (previous MI, angina, stroke, heart failure, secondary&#xD;
             hypertension),&#xD;
&#xD;
          -  renal or hepatic disease (serum creatinine &gt; 0.2 mmol/L; &gt; 1 proteinuria on dipstick;&#xD;
             alanine transferase &gt; 2.5 times upper limit of normal, active liver disease) or&#xD;
&#xD;
          -  diseases which may affect measured parameters (e.g. thyroid, Cushing's or Addison's&#xD;
             diseases).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nora E Straznicky, PhD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baker IDI Heart &amp; Diabetes Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nora E Straznicky, PhD MPH</last_name>
    <phone>61 3 8532 1371</phone>
    <email>nora.straznicky@bakeridi.edu.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mariee T Grima, MDiet</last_name>
    <phone>61 3 8532 1523</phone>
    <email>mariee.grima@bakeridi.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Heart Centre, Alfred Hospital</name>
      <address>
        <city>Prahran, Melbourne</city>
        <state>Victoria</state>
        <zip>3181</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nora E Straznicky, BPharm PhD MPH</last_name>
      <phone>61 3 8532 1371</phone>
      <email>nora.straznicky@bakeridi.edu.au</email>
    </contact>
    <investigator>
      <last_name>Nora E Straznicky, PhD MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>June 12, 2012</study_first_submitted>
  <study_first_submitted_qc>June 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2012</study_first_posted>
  <last_update_submitted>September 8, 2014</last_update_submitted>
  <last_update_submitted_qc>September 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baker Heart Research Institute</investigator_affiliation>
    <investigator_full_name>Nora E. Straznicky</investigator_full_name>
    <investigator_title>Senior Research Officer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metyrapone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

